An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of HEPLISAV to Licensed Vaccine (Engerix-B) Among Adults (18 to 70 Years of Age) With Chronic Kidney Disease (CKD).

Trial Profile

An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of HEPLISAV to Licensed Vaccine (Engerix-B) Among Adults (18 to 70 Years of Age) With Chronic Kidney Disease (CKD).

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs V 270 (Primary) ; Alum; Hepatitis B vaccine recombinant
  • Indications Hepatitis B
  • Focus Pharmacodynamics; Registrational
  • Sponsors Dynavax Technologies
  • Most Recent Events

    • 24 Sep 2013 Results have been published in Vaccine according to a Dynavax Technologies Corporation media release.
    • 27 Mar 2012 Primary endpoint 'Antibody-levels' has been met.
    • 27 Mar 2012 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top